The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 16, 2013
Filed:
Mar. 14, 2008
Sonali Rudra, Gurgaon, IN;
Nidhi Gupta, New Delhi, IN;
Lalit Kumar Baregama, Chittorgarh, IN;
Ritu Agarwal, Hooghly, IN;
Vinayak Vasantrao Khairnar, Nashik, IN;
Mandadapu Raghu Ramaiah, Guntur, IN;
Venkata P. Palle, Pune, IN;
Sarala Balachandran, Mumbai, IN;
Atul Kondaskar, Nagpur, IN;
Manohar Salla, Gurgaon, IN;
Abhijit Ray, New Delhi, IN;
Sunanda G. Dastidar, New Delhi, IN;
Lalitha Vijaykrishnan, New Delhi, IN;
Sonali Rudra, Gurgaon, IN;
Nidhi Gupta, New Delhi, IN;
Lalit Kumar Baregama, Chittorgarh, IN;
Ritu Agarwal, Hooghly, IN;
Vinayak Vasantrao Khairnar, Nashik, IN;
Mandadapu Raghu Ramaiah, Guntur, IN;
Venkata P. Palle, Pune, IN;
Sarala Balachandran, Mumbai, IN;
Atul Kondaskar, Nagpur, IN;
Manohar Salla, Gurgaon, IN;
Abhijit Ray, New Delhi, IN;
Sunanda G. Dastidar, New Delhi, IN;
Lalitha Vijaykrishnan, New Delhi, IN;
Ranbaxy Laboratories Limited, New Delhi, IN;
Abstract
The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed herein having the structure of Formula 1: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukaemia; especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE type 4/PDE type 7 inhibitors are provided.